

119<sup>TH</sup> CONGRESS  
2<sup>D</sup> SESSION

# H. R. 8857

To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.

---

## IN THE HOUSE OF REPRESENTATIVES

MAY 15, 2026

Mr. MORELLE (for himself, Mr. GOTTHEIMER, Mr. PFLUGER, and Mr. KEAN) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Next Generation Medi-  
5 cines Act of 2026” or the “Next GEN Act of 2026”.

1 **SEC. 2. ADJUSTING RULES FOR ENGINEERED CYCLIC**  
2 **PEPTIDES UNDER DRUG PRICE NEGOTIATION**  
3 **PROGRAM.**

4 (a) IN GENERAL.—Section 1192(e) of the Social Se-  
5 curity Act (42 U.S.C. 1320f-1(e)) is amended—

6 (1) in paragraph (1)(A)(ii), by inserting “(or,  
7 in the case of an engineered cyclic peptide (as de-  
8 fined in paragraph (5)), 11 years)” after “7 years”;  
9 and

10 (2) by adding at the end the following new  
11 paragraph:

12 “(5) ENGINEERED CYCLIC PEPTIDE DE-  
13 FINED.—In this subsection, the term ‘engineered cy-  
14 clic peptide’ means a polymer that—

15 “(A) is composed principally of amino  
16 acids;

17 “(B) contains not less than 1 cyclic struc-  
18 ture produced through head-to-tail cyclization,  
19 head-to-side-chain cyclization, side-chain-to-tail  
20 cyclization, or side-chain-to-side-chain cycliza-  
21 tion;

22 “(C) contains not more than 40 amino  
23 acids;

24 “(D) was identified for development using  
25 a genetically encoded library screening method;

26 “(E) is not naturally derived; and

1                   “(F) is orally administered, inhaled, or  
2                   otherwise self-administered.”.

3           (b) EFFECTIVE DATE.—The amendments made by  
4 this section shall apply with respect to lists published  
5 under section 1192(a) of the Social Security Act (42  
6 U.S.C. 1320f–1(a)) on or after the date of the enactment  
7 of this section.

○